Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Sun, Hsin‐Yun; Cheng, Chien-Yu; Lin, Chia-Hsien; Yang, Chia‐Jui; Lee, Nan-Yao; Liou, Bo-Huang; Tang, Hung‐Jen; Liu, Yuang-Meng; Lee, Chun-Yuan; Chen, Tun‐Chieh; Huang, Yi‐Chia; Lee, Yuan‐Ti; Tsai, Ming-Jui; Lu, Po‐Liang; Tsai, Hung-Chin; Wang, Ning‐Chi; Hung, Tung-Che; Cheng, Shu‐Hsing; Hung, Chien‐Ching

doi:10.3748/wjg.v28.i11.1172

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The program had not reimbursed DAA retreatment for those who had ever received NHI-reimbursed DAAs until 2021, when a second course of DAAs could be reimbursed for those who had recurrent HCV infections due to relapse or reinfection. Enrollment in the HCV treatment program with achievement of SVR was high among PLWH ( 31 – 33 ).…”

Section: Methodsmentioning

confidence: 99%

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

et al. 2022

Self Cite

View full text Add to dashboard Cite

The HCV core antigen assay has a high specificity of 99.4% and negative predictive value of 99.5% but a lower sensitivity of 87.1% and positive predictive value of 85.7% in the diagnosis of recently acquired HCV infection in high-risk populations. Our findings are informative for many countries confronted with limited resources to timely identify acute HCV infections and provide effective direct-acting antivirals to halt onward transmission.

show abstract

Section: Methodsmentioning

confidence: 99%

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, only 18% of PWH with HCV co‐infected received anti‐HCV treatment, with the majority receiving interferon‐based therapy. In PWH with HCV and established cirrhosis, use of direct‐acting antivirals and sustained virologic response with either interferon‐based or direct‐acting antiviral therapy were associated with a significantly lower risk of development of HCC 41,42 . Future studies should be performed to evaluate if HIV has any residual impact on development of HCC in PWH with HCV infection receiving direct‐acting antiviral therapy.…”

Section: Discussionmentioning

confidence: 99%

Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection

Lui

Hui

Sze

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundIt is uncertain whether people with HIV infection have a higher incidence of hepatocellular carcinoma (HCC) than the general population.AimsTo compare the incidence of HCC between people infected with HBV and/or HCV with and without HIVMethodsWe performed a retrospective population‐based cohort study, involving people with HBV and/or HCV infection from 2001 to 2018. The primary endpoint was incidence of HCC; secondary endpoint was all‐cause mortality. We performed Cox proportional hazard regression models to estimate the hazard ratios (HR) of HIV for the primary and secondary endpoints.ResultsWe identified 1374 people infected with HIV and 39,908 people without HIV with HBV and/or HCV infection. Among those with HIV, 654 (47.6%) had HBV, 649 (47.2%) HCV and 71 (5.2%) HBV‐HCV‐co‐infection; they were younger, and had a higher prevalence of HCV and a lower prevalence of cirrhosis. The incidence rate estimates of HCC were, respectively, 1.5 (95% CI: 0.8–2.5) and 7.6 (95% CI 7.3‐8.0) per 1000 person‐years for those with and without HIV infection. Using multivariate Cox proportional hazard regression models, among people with HBV, HIV was associated with lower risk of HCC (adjusted HR: 0.376, 95% CI: 0.201–0.704, p = 0.01) and death (adjusted HR: 0.692, 95% CI: 0.552–0.867, p = 0.007). Risks of HCC were similar for HCV and HBV‐HCV co‐infection for people with and without HIV.ConclusionsAmong individuals with HBV infection, the Incidence of HCC was lower in those with HIV. For HCV infection, incidence of HCC was similar between those with and without HIV.

show abstract

Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study

Tsai¹,

Chen²,

Tsai³

et al. 2023

Journal of Microbiology, Immunology and Infection

View full text Add to dashboard Cite

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Cited by 5 publications

References 33 publications

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection

Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study

Contact Info

Product

Resources

About